

# Elisabeth G E De Vries

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6678143/elisabeth-g-e-de-vries-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

440  
papers

29,097  
citations

78  
h-index

158  
g-index

454  
ext. papers

34,487  
ext. citations

8.1  
avg, IF

6.79  
L-index

#	Paper	IF	Citations
440	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	14
439	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.. <i>Nature Reviews Clinical Oncology</i> , <b>2022</b> ,	19.4	16
438	Noise sensitivity of Zr-Immuno-PET radiomics based on count-reduced clinical images.. <i>EJNMMI Physics</i> , <b>2022</b> , 9, 16	4.4	1
437	Zr-PET imaging to predict tumor uptake of Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma.. <i>Scientific Reports</i> , <b>2022</b> , 12, 6286	4.9	0
436	The gut wall as potential as a partner for precision oncology in immune checkpoint treatment.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 107, 102406	14.4	0
435	Clinical Validity of 16[F]Fluoro-17[E]Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200400	2.2	1
434	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1681-1691	21.7	22
433	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , <b>2021</b> ,	7.5	2
432	Improving gene function predictions using independent transcriptional components. <i>Nature Communications</i> , <b>2021</b> , 12, 1464	17.4	6
431	Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	2
430	Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review. <i>JAMA Oncology</i> , <b>2021</b> , 7, 759-770	13.4	1
429	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 4369-4376	8.8	4
428	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1455-1462	7.5	4
427	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study <b>2021</b> , 9,		5
426	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , <b>2021</b> , 151, 72-83	7.5	2
425	PET/CT Imaging of Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys. <i>Molecular Imaging and Biology</i> , <b>2021</b> , 23, 250-259	3.8	10
424	Assessment of Bone Lesions with F-FDG PET Compared with Tc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 177-183	8.9	3

423	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , <b>2021</b> , 27, 568-569	50.5	30
422	First-in-Human Study of the Biodistribution and Pharmacokinetics of Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	3
421	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. <i>Blood Advances</i> , <b>2021</b> , 5, 2958-2964	7.8	4
420	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1367-1377	21.7	13
419	Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 786191	5.3	0
418	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer F-BMS-986192. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1839-1844	8.9	16
417	Probody Therapeutic Design of Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3999-4009	12.9	18
416	Molecular imaging in lymphoma beyond F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. <i>Lancet Haematology,the</i> , <b>2020</b> , 7, e479-e489	14.6	5
415	Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 87, 102027	14.4	1
414	The global imperative to make cancer medications affordable. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 609-610	21.7	0
413	High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 30	8.3	3
412	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2461-2465	12.9	2
411	Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1355-1360	8.9	16
410	Which patients are prone to undergo disproportionate recurrent CT imaging and should we worry?. <i>European Journal of Radiology</i> , <b>2020</b> , 125, 108898	4.7	3
409	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 528-534	13.4	11
408	Neuroendocrine tumours and their microenvironment. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 1449-1459	7.4	4
407	EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , <b>2020</b> , 5,	6	5
406	The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1594-1601	8.9	4

405	Visual and quantitative evaluation of [F]FES and [F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. <i>EJNMMI Research</i> , <b>2020</b> , 10, 40	3.6	5
404	Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model. <i>EJNMMI Research</i> , <b>2020</b> , 10, 111	3.6	9
403	Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5079-5079	2.2	1
402	Mass spectrometric quantification of urinary 6-sulfatoxymelatonin: age-dependent excretion and biological variation. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 59, 187-195	5.9	2
401	PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 antibody therapeutic, as a single agent or in combination with ipilimumab.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3005-3005	2.2	1
400	Transcriptional effects of copy number alterations in a large set of human cancers. <i>Nature Communications</i> , <b>2020</b> , 11, 715	17.4	26
399	Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. <i>ESMO Open</i> , <b>2020</b> , 5, e000681	6	1
398	A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using F-FES PET/CT imaging. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 97	8.3	5
397	Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs <b>2020</b> , 8,		18
396	Visualizing Cancer. <i>Cancer Cell</i> , <b>2020</b> , 38, 753-756	24.3	3
395	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , <b>2020</b> , 141, 171-184	7.5	37
394	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. <i>ESMO Open</i> , <b>2020</b> , 5, e000743	6	4
393	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , <b>2020</b> , 39, 187-203	9.2	19
392	Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers. <i>Pathology and Oncology Research</i> , <b>2020</b> , 26, 1539-1547	2.6	15
391	Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. <i>Cell Reports</i> , <b>2019</b> , 28, 2345-2357.e5	10.6	10
390	Clinical-grade N-(4-[F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2019</b> , 4, 15	5.8	13
389	Melatonin is not stored in platelets. <i>Clinica Chimica Acta</i> , <b>2019</b> , 498, 17-20	6.2	1
388	Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. <i>Clinical Chemistry</i> , <b>2019</b> , 65, 1388-1398	5.5	8

387	Interobserver reproducibility of tumor uptake quantification with Zr-immuno-PET: a multicenter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1840-1849	8.8	8
386	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1124-1135	21.7	127
385	Lesion detection by [Zr]Zr-DFO-girentuximab and [F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1931-1939	8.8	25
384	Consideration of breast cancer subtype in targeting the androgen receptor. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 200, 135-147	13.9	35
383	Shortages of inexpensive essential medicines. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e224-e225	21.7	3
382	A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 201, 103-119	13.9	114
381	Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. <i>ESMO Open</i> , <b>2019</b> , 4, e000460	6	29
380	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. <i>Oncolmmunology</i> , <b>2019</b> , 8, 1558664	7.2	
379	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1102-1110	2.2	24
378	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 336-349	2.2	66
377	ESMO-MCBS: setting the record straight. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e192	21.7	1
376	Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3517-3527	12.9	21
375	Sulfonylurea derivatives and cancer, friend or foe?. <i>European Journal of Pharmacology</i> , <b>2019</b> , 861, 172598	9.3	11
374	RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 2361-2374	7.9	18
373	Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1807	13.4	0
372	Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, xxi	7.3	1
371	89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors. <i>Annals of Oncology</i> , <b>2019</b> , 30, i4	10.3	6
370	A Conversation Between Elisabeth de Vries and Johannes Czernin. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1337-1339	8.9	0

369	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , <b>2019</b> , 4, 1-7	2.7	1
368	Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 1278-1280	25.5	51
367	Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2019</b> , 44, 612-619	1.7	2
366	Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1355-1360	6.7	10
365	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 241-255	19.4	39
364	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. <i>Oncogene</i> , <b>2019</b> , 38, 1477-1488	9.2	7
363	Reply to the letter to the editor <b>ESMO-MCBS v1.1: statistical and patient relevant shortcomings</b> by Emprechtinger et al. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1335-1338	10.3	
362	Reply to the letter to the editor <b>Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies</b> <i>Annals of Oncology</i> , <b>2018</b> , 29, 774-775	10.3	1
361	Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-Ig scaffolds. <i>Medicinal Research Reviews</i> , <b>2018</b> , 38, 1837-1873	14.4	7
360	Use of Video-consultation is Feasible During Follow-up Care of Patients with a Neuroendocrine Tumour. <i>Clinical Oncology</i> , <b>2018</b> , 30, 396	2.8	2
359	Reply to the letter to the editor <b>Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?</b> by Del Paggio. <i>Annals of Oncology</i> , <b>2018</b> , 29, 521-522	10.3	
358	Towards optimal personalized diet and vitamin supplementation in NET patients. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, L23-L26	5.7	3
357	Molecular Imaging in Cancer Drug Development. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 726-732	8.9	29
356	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , <b>2018</b> , 19, e20-e32	21.7	63
355	F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1212-1218	8.9	27
354	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1142-1143	9.7	1
353	Evolution in sentinel lymph node biopsy in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 123, 83-94	7	40
352	Immune Modulation Therapy and Imaging: Workshop Report. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 410-417	8.7	19



351	Potential Red-Flag Identification of Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy. <i>Theranostics</i> , <b>2018</b> , 8, 1458-1467	12.1	34
350	Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1708-1713	3.6	15
349	Molecular Imaging of Radiolabeled Bispecific T-Cell Engager Zr-AMG211 Targeting CEA-Positive Tumors. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4988-4996	12.9	17
348	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 2404-2412	8.8	13
347	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1437	13.4	1
346	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 70, 118-126	14.4	9
345	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative F-FDG PET/CT analysis. <i>EJNMMI Research</i> , <b>2018</b> , 8, 101	3.6	18
344	Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. <i>Nature Medicine</i> , <b>2018</b> , 24, 1852-1858	50.5	277
343	European Academy of Cancer Sciences - position paper. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1829-1837	7.9	6
342	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 70, 232-244	14.4	28
341	Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse. <i>Theranostics</i> , <b>2018</b> , 8, 4295-4304	12.1	32
340	Tumor-associated macrophages in breast cancer: Innocent bystander or important player?. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 70, 178-189	14.4	163
339	Preparing for the incoming wave of biosimilars in oncology. <i>ESMO Open</i> , <b>2018</b> , 3, e000420	6	5
338	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 52-60	7.5	9
337	Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. <i>American Journal of Pathology</i> , <b>2018</b> , 188, 1973-1981	5.8	19
336	Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 905-910	8.9	38
335	Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2730-2741	12.9	152
334	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , <b>2017</b> , 18, e143-e152	21.7	1010

333	Synthesis and Evaluation of the Estrogen Receptor Selective Radioligand 2-F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16F-Fluoro-17Estradiol. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 554-559	8.9	16
332	Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , <b>2017</b> , 46, 751-757	2.6	3
331	Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1210-1215	8.9	31
330	Zr-Onartuzumab PET imaging of c-MET receptor dynamics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1328-1336	8.8	19
329	RECIST - learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 187-192	19.4	53
328	The antibody-drug conjugate target landscape across a broad range of tumour types. <i>Annals of Oncology</i> , <b>2017</b> , 28, 3083-3091	10.3	29
327	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2340-2366	10.3	266
326	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. <i>Theranostics</i> , <b>2017</b> , 7, 2111-2133	12.1	9
325	ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. <i>Oncotarget</i> , <b>2017</b> , 8, 45432-45446	3.3	14
324	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1906-1912	8.9	34
323	Theranostics Using Antibodies and Antibody-Related Therapeutics. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 83S-90S	8.9	75
322	Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. <i>MABs</i> , <b>2017</b> , 9, 1370-1378	8.6	15
321	Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: A Multicenter Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 466-475	4.8	19
320	Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6128-6137	12.9	38
319	In Vivo Quantification of ER Expression by Pharmacokinetic Modeling: Studies with F-FHNP PET. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1743-1748	8.9	5
318	Reply to the letter to the editor Addressing the quality of the ESMO-MCBS by Del Paggio. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2031-2032	10.3	
317	Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment. <i>Clinical Nuclear Medicine</i> , <b>2017</b> , 42, 163-168	1.7	2
316	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1836-1846	59.2	610



315	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	178
314	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 623-631	10.1	30
313	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. <i>ESMO Open</i> , <b>2017</b> , 2, e000216	6	14
312	Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2534-2534	2.2	7
311	Pharmacokinetics of cetuximab and tumor uptake of 89Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15117-e15117	2.2	1
310	Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients <b>2017</b> , 77-96		1
309	Change in metabolic tumor activity on 18F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11519-11519	2.2	
308	Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. <i>Neuroendocrinology</i> , <b>2016</b> , 103, 489-94	5.6	33
307	Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers. <i>Oncologist</i> , <b>2016</b> , 21, 995-1001	5.7	4
306	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3906-3913	2.2	151
305	89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1244-50	8.9	12
304	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma. <i>Familial Cancer</i> , <b>2016</b> , 15, 607-16	3	10
303	RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , <b>2016</b> , 62, 138-45	7.5	117
302	Potential value of EUS in pancreatic surveillance of VHL patients. <i>European Journal of Endocrinology</i> , <b>2016</b> , 174, 611-20	6.5	8
301	Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1030-7	13.4	129
300	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1642-52	12.9	56
299	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57 Suppl 1, 96S-104S	8.9	8
298	Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 812-7	8.9	25

297	Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57 Suppl 1, 81S-8S	8.9	34
296	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 439-47	6.1	68
295	Breaking the DNA damage response to improve cervical cancer treatment. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 42, 30-40	14.4	41
294	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, 619-24	10.3	195
293	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11553-11553	2.2	1
292	A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS627-TPS627	2.2	2
291	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. <i>Oncotarget</i> , <b>2016</b> , 7, 68111-68121	3.3	13
290	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , <b>2016</b> , 7, 21247-58	3.3	79
289	89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11555-11555	2.2	
288	Emerging Opportunities for c-MET Visualization in the Clinic. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 663-4.9	4.9	4
287	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000097	6	59
286	Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 46, 63-72	14.4	10
285	RECIST 1.1-Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , <b>2016</b> , 62, 132-7	7.5	607
284	Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2016</b> , 104, 226-34	5.7	40
283	Gene expression analysis identifies global gene dosage sensitivity in cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 115-25	36.3	219
282	Objective allergy markers and risk of cancer mortality and hospitalization in a large population-based cohort. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 99-109	2.8	11
281	Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: a literature analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 26-37	7	66
280	The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1617-25	8.7	16

279	Regulators of homologous recombination repair as novel targets for cancer treatment. <i>Frontiers in Genetics</i> , <b>2015</b> , 6, 96	4.5	36
278	Rectal and colon cancer: Not just a different anatomic site. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 671-9	14.4	173
277	Immunotherapeutic options on the horizon in breast cancer treatment. <i>Pharmacology &amp; Therapeutics</i> , <b>2015</b> , 156, 90-101	13.9	15
276	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 634-9	4.9	35
275	TGF- $\beta$ Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1310-4	8.9	59
274	Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2305-10	10.3	43
273	Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1674-1681	8.8	32
272	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , <b>2015</b> , 26, 1547-73	10.3	451
271	Rif1 Is Required for Resolution of Ultrafine DNA Bridges in Anaphase to Ensure Genomic Stability. <i>Developmental Cell</i> , <b>2015</b> , 34, 466-74	10.2	53
270	EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. <i>Gastrointestinal Endoscopy</i> , <b>2015</b> , 81, 159-167.e2	5.2	61
269	Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 72-81	24.4	106
268	ATR inhibition preferentially targets homologous recombination-deficient tumor cells. <i>Oncogene</i> , <b>2015</b> , 34, 3474-81	9.2	60
267	Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with $^{90}\text{Zr}$ and IRDye 800CW in mice bearing human pancreatic tumor xenografts. <i>Oncotarget</i> , <b>2015</b> , 6, 42081-90	3.3	28
266	Microenvironment involved in FPR1 expression by human glioblastomas. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 123, 53-63	4.8	6
265	Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 376-84	14.4	36
264	$^{89}\text{Zr}$ -bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 63-9	8.9	79
263	Assessment of estrogen receptor expression in epithelial ovarian cancer patients using $^{16}\text{E}18\text{F}$ -fluoro- $^{17}\text{E}$ estradiol PET/CT. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 50-5	8.9	34
262	Antibody positron emission tomography imaging in anticancer drug development. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1491-504	2.2	78

261	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e270-8	21.7	472
260	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e133-4	2.2	7
259	A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 18-24.e1	3.8	9
258	Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4091-4091	2.2	5
257	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 527-527	2.2	2
256	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3097 <sup>2</sup> -TPS3097		
255	Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage. <i>PLoS ONE</i> , <b>2015</b> , 10, e0115372	3.7	27
254	Human stromal cells are required for an anti-breast cancer effect of zoledronic acid. <i>Oncotarget</i> , <b>2015</b> , 6, 24436-47	3.3	6
253	Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. <i>Oncotarget</i> , <b>2015</b> , 6, 28164-72	3.3	18
252	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 2276-83	3.3	10
251	Bleomycin-induced pulmonary changes on restaging CT scans: Frequency and correlation with fibrosis markers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4540-4540	2.2	
250	HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting. <i>Pharmacology &amp; Therapeutics</i> , <b>2014</b> , 143, 1-11	13.9	49
249	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet, The</i> , <b>2014</b> , 383, 2127-35	40	1237
248	Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 135-44	4.3	31
247	Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1087-92	8.9	45
246	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R47	8.3	70
245	In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 665-71	8.9	34
244	Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2508-16	7.5	13

243	The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1847-1853	7.5	23
242	(111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. <i>Molecular Imaging</i> , <b>2014</b> , 13,	3.7	29
241	CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. <i>Clinical and Experimental Metastasis</i> , <b>2014</b> , 31, 829-39	4.7	28
240	89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3945-54	12.9	83
239	ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody $^{125}$ I-RG7116. <i>MABs</i> , <b>2014</b> , 6, 1051-8	6.6	44
238	Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics". <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	18
237	Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. <i>Drug Resistance Updates</i> , <b>2014</b> , 17, 96-104	23.2	40
236	APC/C(Cdh1) controls CtIP stability during the cell cycle and in response to DNA damage. <i>EMBO Journal</i> , <b>2014</b> , 33, 2860-79	13	44
235	Considerations on absence of $^{68}$ Ga-DOTA-F(ab) $_{2}$ -trastuzumab tracer uptake in HER2-overexpressing tumor lesions. <i>Nuclear Medicine Communications</i> , <b>2014</b> , 35, 785-6	1.6	1
234	Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, 63-71	5.7	31
233	Video-rate optical flow corrected intraoperative functional fluorescence imaging. <i>Journal of Biomedical Optics</i> , <b>2014</b> , 19, 046012	3.5	1
232	Dispelling the myths around cancer care delivery: It's not all about costs. <i>Journal of Cancer Policy</i> , <b>2014</b> , 2, 22-29	1	23
231	PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11001-11001	2.2	10
230	Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11095-11095 <sup>5</sup>		
229	Prospective analysis of serial FLT-PET scanning to discriminate between true and pseudoprogression in glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2009-2009	2.2	2
228	A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2529-2529	2.2	4
227	Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 588-588	2.2	
226	89Zr-bevacizumab PET imaging of disease manifestations in patients with Von Hippel-Lindau disease.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11090-11090	2.2	

225	Hemodialysis no reason to withhold everolimus. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 273-4	3.5	4
224	Inhibition of formyl peptide receptor in high-grade astrocytoma by Chemotaxis Inhibitory Protein of <i>S. aureus</i> . <i>British Journal of Cancer</i> , <b>2013</b> , 108, 587-96	8.7	18
223	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology</i> , <b>2013</b> , 14, e465-475	13.4	134
222	A review on CXCR4/CXCL12 axis in oncology: no place to hide. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 219-29	7.9	428
221	Targeting FLIP and Mcl-1 using a combination of aspirin and Sorafenib sensitizes colon cancer cells to TRAIL. <i>Journal of Pathology</i> , <b>2013</b> , 229, 410-21	9.4	23
220	Effect of vemurafenib on a V600R melanoma brain metastasis. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1795-6	7.5	6
219	Translating TRAIL-receptor targeting agents to the clinic. <i>Cancer Letters</i> , <b>2013</b> , 332, 194-201	9.9	61
218	Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. <i>Oncogene</i> , <b>2013</b> , 32, 3001-8	9.2	91
217	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , <b>2013</b> , 717, 2-11	5.3	11
216	Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 2685-95	8.7	29
215	Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies--response. <i>Cancer Research</i> , <b>2013</b> , 73, 7147-8	10.1	7
214	Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. <i>Cancer Research</i> , <b>2013</b> , 73, 3347-55	10.1	85
213	89Zr-bevacizumab PET imaging in primary breast cancer. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 1014-8	8.9	119
212	Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 929-35	8.9	13
211	Endothelial damage in long-term survivors of childhood cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3906-13	2.2	38
210	HIF-1 $\beta$ overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. <i>PLoS ONE</i> , <b>2013</b> , 8, e56055	3.7	28
209	89Zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2050-2050	2.2	7
208	Tailored imaging of islet cell tumors of the pancreas amidst increasing options. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 82, 213-26	7	8



207	Transforming growth factor (TGF)- $\beta$ expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. <i>Pharmacology &amp; Therapeutics</i> , <b>2012</b> , 135, 123-32	13.9	30
206	Lapatinib and 17AAG reduce $^{89}\text{Zr}$ -trastuzumab-F(ab) $_{\text{2}}$ uptake in SKBR3 tumor xenografts. <i>Molecular Pharmaceutics</i> , <b>2012</b> , 9, 2995-3002	5.6	38
205	Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. <i>British Journal of Pharmacology</i> , <b>2012</b> , 165, 2203-12	8.6	11
204	Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 84, 224-42	7	7
203	Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. <i>Cell Cycle</i> , <b>2012</b> , 11, 4552-62	4.7	26
202	CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. <i>Neoplasia</i> , <b>2012</b> , 14, 709-18	6.4	135
201	The role of ATM and 53BP1 as predictive markers in cervical cancer. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2056-66	7.5	27
200	Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. <i>Experimental Hematology</i> , <b>2012</b> , 40, 177-186.e6	3.1	12
199	Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e74-5	2.2	30
198	Measurement of tumor VEGF-A levels with $^{89}\text{Zr}$ -bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6306-14	12.9	50
197	Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. <i>Leukemia</i> , <b>2012</b> , 26, 845-8	10.7	11
196	Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells. <i>Molecular Pharmacology</i> , <b>2012</b> , 81, 701-9	4.3	33
195	PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 182-90	8.9	105
194	Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 3784-92	3.3	15
193	$^{89}\text{Zr}$ -bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10581-10581	2.2	9
192	The components of progression as explanatory variables for overall survival in the RECIST database.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10602-10602	2.2	
191	Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4528-4528	2.2	
190	Macrophage inhibitory cytokine 1 plasma levels in testicular cancer patients during cisplatin combination treatment and their relation to endothelial damage.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e15035-e15035	2.2	

189	Everolimus for advanced pancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 514-23	59.2	2101
188	VEGF-SPECT with $\alpha$ n-bevacizumab in stage III/IV melanoma patients. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1595-602	7.5	46
187	Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 2453-62	7.5	42
186	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. <i>Lancet, The</i> , <b>2011</b> , 378, 771-84	40	1935
185	Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. <i>Lancet, The</i> , <b>2011</b> , 378, 1707-16	40	2287
184	Targeting TRAIL towards the clinic. <i>Current Drug Targets</i> , <b>2011</b> , 12, 2079-90	3	20
183	A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. <i>Oncogene</i> , <b>2011</b> , 30, 2026-36	9.2	18
182	Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1278-87	8.7	28
181	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 80, 264-77	7	8
180	Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 38, 1854-61	8.8	35
179	TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. <i>Journal of Pathology</i> , <b>2011</b> , 223, 378-89	9.4	8
178	Current status and future developments of LC-MS/MS in clinical chemistry for quantification of biogenic amines. <i>Clinical Biochemistry</i> , <b>2011</b> , 44, 95-103	3.5	57
177	The chemokine network, a newly discovered target in high grade gliomas. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 79, 154-63	7	25
176	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 1778-85	8.9	165
175	PET with the 89Zr-labeled transforming growth factor- $\beta$ antibody fresolimumab in tumor models. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 2001-8	8.9	41
174	Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2286-93	10.3	34
173	Toward molecular imaging-driven drug development in oncology. <i>Cancer Discovery</i> , <b>2011</b> , 1, 25-8	24.4	20
172	Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. <i>Oncologist</i> , <b>2011</b> , 16, 783-7	5.7	54

171	High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3214-23	2.2	72
170	VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. <i>Cancer Research</i> , <b>2011</b> , 71, 143-53	10.1	94
169	Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1317-30	12.9	101
168	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1561-1570	10.3	131
167	Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 431-6	8.9	9
166	<sup>89</sup> Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 761-7	8.9	98
165	Elevated urinary free and deconjugated catecholamines after consumption of a catecholamine-rich diet. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 2851-5	5.6	13
164	Receptor conversion in distant breast cancer metastases. <i>Breast Cancer Research</i> , <b>2010</b> , 12, R75	8.3	157
163	( <sup>89</sup> Zr)-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 678-84	7.5	75
162	Metformin: taking away the candy for cancer?. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 2369-80	7.5	310
161	Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 364-8	3.2	2
160	Automated mass spectrometric analysis of urinary and plasma serotonin. <i>Analytical and Bioanalytical Chemistry</i> , <b>2010</b> , 396, 2609-16	4.4	50
159	Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 611-7	2.8	28
158	Automated mass spectrometric analysis of urinary free catecholamines using on-line solid phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2010</b> , 878, 1506-12	3.2	49
157	The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. <i>Quality of Life Research</i> , <b>2010</b> , 19, 137-48	3.7	18
156	Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2010</b> , 1805, 123-40	11.2	82
155	The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2010</b> , 116, 549-55	4.9	37
154	Sexual function in patients with metastatic midgut carcinoid tumours. <i>Neuroendocrinology</i> , <b>2009</b> , 89, 231-6	5.6	12

153	Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2048-57	12.9	43
152	Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5584-90	12.9	94
151	Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 974-81	8.9	268
150	Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3076-83	12.9	26
149	Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2841-9	5.6	106
148	6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2822-30	5.6	128
147	Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells. <i>Journal of Biological Inorganic Chemistry</i> , <b>2009</b> , 14, 123-32	3.7	10
146	The prognostic value of TRAIL and its death receptors in cervical cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 203-11	4	26
145	Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 115, 573-80	4.4	46
144	Fas ligand expression in lynch syndrome-associated colorectal tumours. <i>Pathology and Oncology Research</i> , <b>2009</b> , 15, 399-406	2.6	4
143	Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells. <i>Annals of Hematology</i> , <b>2009</b> , 88, 573-80	3	9
142	Analyzing longitudinal data with patients in different disease states during follow-up and death as final state. <i>Statistics in Medicine</i> , <b>2009</b> , 28, 3829-43	2.3	11
141	Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 149-59	8.7	89
140	Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 603-9	3.2	81
139	Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 199-213	7	117
138	Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2312-5	7.5	10
137	Improvements in small bowel carcinoid diagnosis and staging: 18F-DOPA PET, capsule endoscopy and double balloon enteroscopy. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, e35-8	3.3	10
136	Cardiovascular toxicity caused by cancer treatment: strategies for early detection. <i>Lancet Oncology</i> , <b>2009</b> , 10, 391-9	21.7	195

135	Role of chemokines and their receptors in cancer. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3396-416	3.3	51
134	Survival-related profile, pathways, and transcription factors in ovarian cancer. <i>PLoS Medicine</i> , <b>2009</b> , 6, e24	11.6	133
133	Serotonin rising. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2580-1; author reply 2581-2	59.2	3
132	Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 42, 475-81	4.4	6
131	The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 341-9	8.7	72
130	Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. <i>BMC Cancer</i> , <b>2008</b> , 8, 389	4.8	17
129	Low plasma tryptophan in carcinoid patients is associated with increased urinary cortisol excretion. <i>Psychoneuroendocrinology</i> , <b>2008</b> , 33, 1297-301	5	4
128	Targeting TRAIL death receptors. <i>Current Opinion in Pharmacology</i> , <b>2008</b> , 8, 433-9	5.1	32
127	The influence of endocrine treatments for breast cancer on health-related quality of life. <i>Cancer Treatment Reviews</i> , <b>2008</b> , 34, 640-55	14.4	54
126	Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. <i>Neoplasia</i> , <b>2008</b> , 10, 1041-8	6.4	68
125	Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1489-95	2.2	218
124	Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1239-46	2.2	142
123	Images in cardiovascular medicine: myocardial metastases of carcinoid visualized by 18F-dihydroxy-phenyl-alanine positron emission tomography. <i>Circulation</i> , <b>2008</b> , 118, 1602-4	16.7	17
122	Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours. <i>Acta Oncologica</i> , <b>2008</b> , 47, 153-5	3.2	1
121	Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. <i>Cancer Research</i> , <b>2008</b> , 68, 7183-90	10.1	48
120	18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 524-31	8.9	106
119	Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 3348-62	3.3	27
118	A new perspective on transcriptional system regulation (TSR): towards TSR profiling. <i>PLoS ONE</i> , <b>2008</b> , 3, e1656	3.7	11

117	Urinary 5-HIAA measurement using automated on-line solid-phase extraction-high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2008</b> , 868, 28-33	3.2	33
116	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 110, 189-97	4.4	88
115	A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 1457-65	7.5	14
114	Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 543-52	4	22
113	Immuno-PET: a navigator in monoclonal antibody development and applications. <i>Oncologist</i> , <b>2007</b> , 12, 1379-89	5.7	260
112	Evidence based selection of housekeeping genes. <i>PLoS ONE</i> , <b>2007</b> , 2, e898	3.7	527
111	Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. <i>Journal of Biochemical and Molecular Toxicology</i> , <b>2007</b> , 21, 243-51	3.4	40
110	ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. <i>Critical Reviews in Oncology/Hematology</i> , <b>2007</b> , 62, 214-26	7	73
109	Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5403-9	2.2	22
108	Serum HER2 levels are increased in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 173-7	12.3	45
107	Translating pharmacogenomics: challenges on the road to the clinic. <i>PLoS Medicine</i> , <b>2007</b> , 4, e209	11.6	120
106	Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 1763-71	3.5	23
105	Profiling studies in ovarian cancer: a review. <i>Oncologist</i> , <b>2007</b> , 12, 960-6	5.7	56
104	Beware of amenorrhea during tamoxifen: it may be a wolf in sheep@ clothing. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3787-8; author reply 3788-9	2.2	11
103	Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1684-93	5.5	119
102	Hot flushes in breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 57, 63-77	7	50
101	Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells. <i>Experimental Hematology</i> , <b>2006</b> , 34, 622-30	3.1	26
100	Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 1892-900	7.5	43



99	Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. <i>Acta Oncologica</i> , <b>2006</b> , 45, 175-83	3.2	19
98	TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4350-6	12.9	26
97	Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2390-3	12.9	51
96	Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1760-7	12.9	20
95	Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2276-82	2.2	231
94	Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. <i>Lancet Oncology</i> , <b>2006</b> , 7, 728-34	21.7	208
93	The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association?. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 465-74	3.1	33
92	Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 682-8	5.1	50
91	The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients. <i>Anticancer Research</i> , <b>2006</b> , 26, 3803-11	2.3	4
90	Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. <i>Lancet Oncology</i> , <b>2005</b> , 6, 589-98	21.7	37
89	Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2005</b> , 37, 2437-56	5.6	48
88	Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. <i>Psychosomatic Medicine</i> , <b>2005</b> , 67, 773-7	3.7	37
87	A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 25-30	3.2	30
86	The dilemma of the strive for apoptosis in oncology: mind the heart. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 53, 101-13	7	9
85	Automated on-line solid-phase extraction coupled with HPLC for measurement of 5-hydroxyindole-3-acetic acid in urine. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1698-703	5.5	28
84	New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. <i>British Journal of Pharmacology</i> , <b>2005</b> , 145, 1045-51	8.6	40
83	Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid. <i>Gynecologic Oncology</i> , <b>2005</b> , 97, 353-64	4.9	38
82	Colorectal cancer and the CHEK2 1100delC mutation. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 43, 377-82	5	25

81	Abdominal angina in patients with a midgut carcinoid, a sign of severe pathology. <i>World Journal of Surgery</i> , <b>2005</b> , 29, 1139-42	3.3	13
80	Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. <i>Human Genetics</i> , <b>2005</b> , 116, 247-54	6.3	35
79	The human leukocyte antigen region and colorectal cancer risk. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 303-6	3.1	6
78	Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1455-62	2.2	53
77	Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8661-8	12.9	94
76	Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8296-304	2.2	78
75	Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5188-97	2.2	87
74	Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4457-63	12.9	37
73	Complications of midgut carcinoid tumors and carcinoid syndrome. <i>Neuroendocrinology</i> , <b>2004</b> , 80 Suppl 1, 28-32	5.6	33
72	Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. <i>Oncogene</i> , <b>2004</b> , 23, 4862-72	9.2	36
71	Preclinical characterisation of 111In-DTPA-trastuzumab. <i>British Journal of Pharmacology</i> , <b>2004</b> , 143, 99-106	12.5	125
70	No association between two MLH3 variants (S845G and P844L) and colorectal cancer risk. <i>Cancer Genetics and Cytogenetics</i> , <b>2004</b> , 152, 70-1		14
69	Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2004</b> , 130, 581-90	4.9	7
68	Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: no additional value of higher scan dose. <i>Annals of Nuclear Medicine</i> , <b>2004</b> , 18, 641-6	2.5	5
67	In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 131-8	3.5	51
66	Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ). <i>International Journal of Cancer</i> , <b>2004</b> , 109, 412-7	7.5	20
65	Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 220-9	6.1	68
64	Breast cancer resistance protein (BCRP) in acute leukemia. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 649-54	1.9	32

63	Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. <i>Drug Resistance Updates</i> , <b>2004</b> , 7, 345-58	23.2	131
62	Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?. <i>Cancer Treatment Reviews</i> , <b>2004</b> , 30, 37-51	14.4	59
61	Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. <i>Shock</i> , <b>2004</b> , 22, 186-8	3.4	20
60	Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. <i>Psychosomatic Medicine</i> , <b>2004</b> , 66, 422-5	3.7	26
59	The HLA class III subregion is responsible for an increased breast cancer risk. <i>Human Molecular Genetics</i> , <b>2003</b> , 12, 2311-9	5.6	35
58	Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 586-93	5.5	49
57	Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4364-70	2.2	112
56	High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 7-16	59.2	217
55	Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 433-40	3.2	25
54	Tryptophan as a link between psychopathology and somatic states. <i>Psychosomatic Medicine</i> , <b>2003</b> , 65, 665-71	3.7	77
53	Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2003</b> , 51, 167-73	3.5	8
52	Pilot study of vaginal plethysmography in women treated with radiotherapy for gynecological cancer. <i>Gynecologic Oncology</i> , <b>2003</b> , 91, 540-6	4.9	14
51	Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. <i>International Journal of Cancer</i> , <b>2003</b> , 106, 611-618	7.5	38
50	Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. <i>Journal of Pathology</i> , <b>2003</b> , 200, 327-35	9.4	108
49	The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli. <i>Journal of Pathology</i> , <b>2003</b> , 200, 137-48	9.4	64
48	High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44, 85-95	1.9	37
47	Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [ <sup>11</sup> C]verapamil measured with PET. <i>NeuroImage</i> , <b>2003</b> , 20, 1775-82	7.9	66
46	Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?. <i>Drug Resistance Updates</i> , <b>2003</b> , 6, 165-7	23.2	5

45	Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. <i>Journal of Nuclear Medicine</i> , <b>2003</b> , 44, 184-91	8.9	58
44	Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3397-405	12.9	85
43	The role of breast cancer resistance protein in acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5171-7	12.9	37
42	Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1222-31	2.2	37
41	JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. <i>Biochemical Pharmacology</i> , <b>2002</b> , 63, 1989-96	6	62
40	S-decyl-glutathione nonspecifically stimulates the ATPase activity of the nucleotide-binding domains of the human multidrug resistance-associated protein, MRP1 (ABCC1). <i>FEBS Journal</i> , <b>2002</b> , 269, 3470-8		7
39	Fas receptor-mediated apoptosis: a clinical application?. <i>Journal of Pathology</i> , <b>2002</b> , 196, 125-34	9.4	105
38	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. <i>Cancer and Metastasis Reviews</i> , <b>2002</b> , 21, 167-83	9.6	29
37	Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. <i>Thyroid</i> , <b>2002</b> , 12, 381-7	6.2	74
36	Calcium or resistant starch does not affect colonic epithelial cell proliferation throughout the colon in adenoma patients: a randomized controlled trial. <i>Nutrition and Cancer</i> , <b>2002</b> , 43, 31-8	2.8	15
35	Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. <i>Blood</i> , <b>2002</b> , 99, 3763-70	2.2	106
34	The role of apoptosis-related genes in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2002</b> , 4, 174-82	4.9	7
33	Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. <i>American Journal of Human Genetics</i> , <b>2002</b> , 70, 26-37	11	246
32	An oncological view on the blood-testis barrier. <i>Lancet Oncology</i> , <b>2002</b> , 3, 357-63	21.7	135
31	Profiling of Tryptophan-related Plasma Indoles in Patients with Carcinoid Tumors by Automated, On-Line, Solid-Phase Extraction and HPLC with Fluorescence Detection. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1817-1820	5.5	81
30	TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS. <i>Obstetrics and Gynecology</i> , <b>2001</b> , 97, 855-860	4.6	57
29	Routine bone scintigraphy in primary staging of soft tissue sarcoma; Is it worthwhile?. <i>Cancer</i> , <b>2000</b> , 89, 1726-31	6.4	29
28	One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults. <i>Clinical Endocrinology</i> , <b>2000</b> , 52, 457-62	3.4	17

27	Discriminating Capacity of Indole Markers in the Diagnosis of Carcinoid Tumors. <i>Clinical Chemistry</i> , <b>2000</b> , 46, 1588-1596	5.5	103
26	The (patho)physiological functions of the MRP family. <i>Drug Resistance Updates</i> , <b>2000</b> , 3, 289-302	23.2	78
25	ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. <i>British Journal of Pharmacology</i> , <b>1999</b> , 126, 681-8	8.6	212
24	Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. <i>International Journal of Cancer</i> , <b>1999</b> , 81, 236-42	7.5	24
23	Telomerase targeting in cancer treatment: new developments. <i>Drug Resistance Updates</i> , <b>1999</b> , 2, 104-115	3.2	15
22	Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. <i>FEBS Journal</i> , <b>1998</b> , 252, 140-6		39
21	Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. <i>Hepatology</i> , <b>1998</b> , 28, 971-9	11.2	103
20	Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. <i>International Journal of Cancer</i> , <b>1998</b> , 76, 55-62	7.5	49
19	Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplatin-sensitive and resistant human embryonal carcinoma cell line. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 41, 469-76	3.5	36
18	Renal toxicity of the anticancer drug fostriecin. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42, 160-4	3.5	11
17	Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. <i>International Journal of Cancer</i> , <b>1996</b> , 67, 800-7	7.5	30
16	Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. <i>Cancer</i> , <b>1995</b> , 75, 1004-9	6.4	38
15	5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. <i>Cancer</i> , <b>1995</b> , 75, 1072-6	6.4	6
14	Sensitization to cisplatin action by step-down heating in cDDP-sensitive and -resistant cells. <i>International Journal of Cancer</i> , <b>1995</b> , 61, 722-6	7.5	11
13	Tumor progression in a giant cell type malignant fibrous histiocytoma of bone: clinical, radiologic, histologic, and cytogenetic evidence. <i>Genes Chromosomes and Cancer</i> , <b>1994</b> , 10, 66-70	5	9
12	Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro. <i>Pharmaceutical Research</i> , <b>1994</b> , 11, 1265-9	4.5	2
11	Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. <i>International Journal of Cancer</i> , <b>1993</b> , 53, 110-7	7.5	14
10	Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro. <i>International Journal of Cancer</i> , <b>1993</b> , 55, 330-7	7.5	10

9	HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>1993</b> , 36, 198-204	7.4	14
8	Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions. <i>Pharmaceutical Research</i> , <b>1992</b> , 9, 808-11	4.5	9
7	Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. <i>Cancer</i> , <b>1991</b> , 67, 2826-7	6.4	54
6	Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1991</b> , 28, 461-4	3.5	27
5	A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1989</b> , 25, 202-4	3.5	12
4	Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review. <i>Pharmaceutisch Weekblad</i> , <b>1988</b> , 10, 237-45		7
3	Renal dysfunction following high-dose carboplatin treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1988</b> , 114, 212-4	4.9	10
2	A patient education program for a continuous infusion regimen on an outpatient basis. <i>Cancer Nursing</i> , <b>1987</b> , 10, 177-82	2.6	9
1	TNO-6-induced acute renal failure. A case report. <i>Cancer</i> , <b>1985</b> , 56, 1511-4	6.4	3